Gastroenterology · Ulcerative ColitisTrial Updateclinicalmid-term

Eli Lilly's LY4268989 Study with Mirikizumab in Ulcerative Colitis Underway

The ongoing clinical trial of LY4268989 in combination with Mirikizumab is significant as it could enhance Eli Lilly's competitive positioning in the ulcerative colitis market. Positive outcomes may lead to a stronger portfolio and increased market share against existing therapies.

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Eli Lilly39 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:31:19 AM

Assessment confidence: 85% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

Strategic Assessment

Success in this trial may enhance Eli Lilly's portfolio in ulcerative colitis and strengthen its market position against existing therapies. The strongest clinical anchor is LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: (ClinicalTrials.gov), entity match (eli lilly). In Gastroenterology · Ulcerative Colitis, 0 regulatory and 2 competitive items passed relevance filtering for Eli Lilly.

Competitive Pressure

The most relevant competitive pressure comes from Lilly to present positive Phase 3 results for pirtobrutinib in CLL at EHA 2026 (Humanexa Signals) — sponsor/company relevance (lilly). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This trial could position Eli Lilly favorably against competitors in the ulcerative colitis space, particularly if the combination shows superior efficacy.

Regulatory Outlook

Regulatory risk is concentrated around Successful trial results could facilitate a favorable regulatory review process, impacting approval timelines and labeling for the combination therapy..

Key Risks

Elevated medium regulatory exposure for Eli Lilly could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
Clinical risk from ClinicalTrials.gov (The Dietary Guidelines 3 Diets Study) could weigh on Eli Lilly through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If the trial demonstrates superior efficacy, Eli Lilly could capture a larger share of the ulcerative colitis market, potentially translating into significant revenue growth.
Hematology · CLL · Trial Update · This data may strengthen Lilly's position in the hematology market, particularly against competitors in CLL therapies.
Upside for Eli Lilly may improve if A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: NewLink Genetics Corporation. The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.
Success in this trial may enhance Eli Lilly's portfolio in ulcerative colitis and strengthen its market position against existing therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes over the next 118 weeks.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

No evidence in this category.

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
ClinicalTrials.govhigh relevance
Entity match (eli lilly)
FDA document
View source
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
The Dietary Guidelines 3 Diets Study
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Sig
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Lilly to present positive Phase 3 results for pirtobrutinib in CLL at EHA 2026
Humanexa Signalshigh relevance
Sponsor/company relevance (Lilly)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Early effects of HPV vaccination on high-grade cervical intraepithelial neoplasia in Brazil: Evidence from outpatient data.
PubMedhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Eli Lilly
Mirikizumab

Commercial impact

medium

If the trial demonstrates superior efficacy, Eli Lilly could capture a larger share of the ulcerative colitis market, potentially translating into significant revenue growth.

Regulatory impact

medium

Successful trial results could facilitate a favorable regulatory review process, impacting approval timelines and labeling for the combination therapy.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes over the next 118 weeks.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.